229 related articles for article (PubMed ID: 26046132)
1. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
[TBL] [Abstract][Full Text] [Related]
2. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
3. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
[TBL] [Abstract][Full Text] [Related]
4. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
5. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
6. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
7. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
8. Antibody internalization studied using a novel IgG binding toxin fusion.
Mazor Y; Barnea I; Keydar I; Benhar I
J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
[TBL] [Abstract][Full Text] [Related]
9. Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.).
Mirzaee M; Jalali-Javaran M; Moieni A; Zeinali S; Behdani M
Plant Mol Biol; 2018 May; 97(1-2):103-112. PubMed ID: 29633168
[TBL] [Abstract][Full Text] [Related]
10. Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.
Altai M; Liu H; Orlova A; Tolmachev V; Gräslund T
Int J Oncol; 2016 Sep; 49(3):1185-94. PubMed ID: 27573289
[TBL] [Abstract][Full Text] [Related]
11.
Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
[TBL] [Abstract][Full Text] [Related]
12. [Bifunctional Toxin DARP-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics].
Proshkina GM; Kiseleva DV; Shilova ON; Ryabova AV; Shramova EI; Stremovskiy OA; Deyev SM
Mol Biol (Mosk); 2017; 51(6):997-1007. PubMed ID: 29271963
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.
Waldron NN; Kaufman DS; Oh S; Inde Z; Hexum MK; Ohlfest JR; Vallera DA
Mol Cancer Ther; 2011 Oct; 10(10):1829-38. PubMed ID: 21862685
[TBL] [Abstract][Full Text] [Related]
14. Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
Amoozadeh S; Hemmati M; Farajollahi MM; Akbari N; Tarighi P
Cancer Invest; 2019; 37(10):546-557. PubMed ID: 31597492
[TBL] [Abstract][Full Text] [Related]
15. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
[TBL] [Abstract][Full Text] [Related]
16. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
17. [Construction, expression and functional characterization of disulfide-stabilized anti-hepatocarcinoma single chain Fv fused with truncated Pseudomonas exotoxin].
Zhao J; Sun ZW; Liu YF; Yu WY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Nov; 19(6):585-7. PubMed ID: 15182657
[TBL] [Abstract][Full Text] [Related]
18. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
19. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]